Figure 3.
ER+: odds ratios for developing an estrogen receptor-positive invasive breast cancer among women involved in tamoxifen prevention trials.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.